Clinical trials · California
Castration Resistant Prostatic Cancer clinical trials in California
We’re tracking 87 recruiting castration resistant prostatic cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Duarte, CaliforniaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Duarte, CaliforniaAges 18–99 - NCT07050433Recruiting
A study for men with advanced prostate cancer on a specific clinical trial
This study looks at men with metastatic castration-resistant prostate cancer who are already taking part in the SYNGERY-201 clinical trial. The goal is to understand how treatments work and how to best support patients.
San Francisco, CaliforniaAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Duarte, CaliforniaAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Duarte, CaliforniaAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Irvine, CaliforniaAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Anaheim, CaliforniaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
San Diego, CaliforniaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Anaheim, CaliforniaAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Los Angeles, CaliforniaAges 18–100 - NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Duarte, CaliforniaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Irvine, CaliforniaAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
San Diego, CaliforniaAges 18 years+
Castration Resistant Prostatic Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting castration resistant prostatic cancer studies listed above.
- City of Hope Comprehensive Cancer Center · 8 studies
- University of California, San Francisco · 5 studies
- University of California, Irvine Medical Center / UC Irvine Health · 4 studies
- University of California, Los Angeles (UCLA) · 4 studies
- Stanford Cancer Center · 3 studies
- University of California San Diego Health · 3 studies
- Cancer and Blood Specialty Clinic · 2 studies
- Cedars-Sinai Medical Center · 2 studies
What taking part in a castration resistant prostatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Castration Resistant Prostatic Cancer trials in other states
Common questions
- Are there castration resistant prostatic cancer clinical trials in California?
- Yes. We're currently tracking 87 recruiting castration resistant prostatic cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a castration resistant prostatic cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a castration resistant prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New castration resistant prostatic cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.